Register for our free email digests:
Division of Amicus Therapeutics Inc.
Latest From Scioderm Inc.
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
FDA started off 2016 with a spate of new breakthrough therapy designations, feeding the popular program – and fueling agency concerns about workforce strain.
Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.
Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Amicus Therapeutics Inc.
- Senior Management
Robert Ryan, PhD, Pres. & CEO
Ron Nardi, PhD, CSO
- Contact Info
Phone: (919) 328-2020
1007 Slater Rd.
Durham, NC 27703
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.